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Abstract
By their nature, stem cells present a strong potential in regenerative medicine. Recent
medical research is noticing this potential as stem cell therapies are becoming more and more
commonplace. With new therapies being proposed and developed, questions are raised about the
specific factors that play significant roles in affecting the biology of these cells. The research focus
of our group is bone tissue regeneration, and we use the mouse MC 3T3-E1 preosteoblast cell line
as a model to study changes during bone cell differentiation. These cells are studied to establish
molecular and cellular assays to assess bone cell proliferation, differentiation, and visualization.
The results from these cells will then be translated to adult stem cells undergoing bone formation.
Cell proliferation assays were validated to obtain the optimal seeding density and optimal fetal
bovine serum contained in the medium for growth and expansion of MC 3T3-E1 cells. Optimal
concentrations of the biological factors dexamethasone, ascorbic acid, and betaglycerophosphate
required for efficient bone cell differentiation have also been optimized. The differentiation
process was evaluated microscopically and confirmed by a calcium-specific staining.
Undifferentiated cells were used as controls. For clinical application, we did a dose curve to assess
the concentration of tobramycin, an antibiotic that is administered subsequent to the addition of
stem cells to damaged joints. Cells showed surprising tolerance to tobramycin between 0 to 360
g/mL. The proliferation of cells suffered significantly at doses greater than 360 g/mL. Further
experiments are currently in progress to study and visualize MC 3T3-E1 cells. These include the
development of a DNA plasmid to visualize bone cell differentiation consisting of a green
fluorescent protein under the control of the osteocalcin promoter with a constitutively active mcherry protein. Additionally, we are studying stem cell behavior on a novel polymerhydroxyapatite – based biocomposite material with a long term goal of using it in bone defect
regeneration.

Introduction
The discovery of stem cells has
opened the door to many new therapies that
were impossible a few decades ago. In
developing zygotes and fetuses, stem cells
are the first cells that mature into the many
tissues of the body. In adults, there are
stockpiles of stem cells that serve to replenish

These cells throughout the life of the
organism. Stem cells are often quick to divide
and expand, and they have the ability to
become many different cells (multipotency).
By utilizing this natural process of cell
replacement, stem cell therapies produce new
tissues for a variety of maladies [1]. Stem

cells from a different individual can be given
as an allograft transplant to provide some
advantage that the patient’s own tissues do
not afford [2]. Alternatively, a patient’s own
stem cells (autograft) can be modified and
replaced to produce therapeutic effects such
as specific gene knockouts [3]. Finally,
though not exhaustively, stem cells can be
removed and expanded from an individual
and then returned in a new location or in large
number to provide a benefit to the patient [4].
Stem cells can generally be divided
into four categories: embryonic stem cells,
fetal stem cells, induced pluripotent stem
cells (iPS), and somatic/adult stem cells.
Embryonic and fetal stem cells are derived
from developing organisms. While they
represent many possible directions in
medicine, these sources of stem cells carry
the risk of hyperproliferation and cancer
formation, and their collection in humans is
often politicized and ethically debated. iPS
cells are produced by treatment of lineagerestricted cells with transcription factors that
result in pluripotency [1]. This is another
promising route for stem cell therapy, but
degrees of uncertainty in the methods for iPS
creation and iPS biology represent challenges
to their use in humans [5]. Considering the
issues with the above methods, adult-derived
somatic stem cells remain the best candidate
for most stem cell treatments. Mesenchymal
Stem Cells (MSC) are somatic stem cells that
have the capacity to differentiate into tissues
of the blood, cartilage, bone, and more. They
can be isolated from bone marrow and fat
tissues and serve as reasonably safe, reliable
sources of stem cells [1].
The capability of MSCs to
differentiate into the cells of the skeletal
system make them ideal for use in bone tissue
regeneration. For most bone defects, such as
fractures, bone regenerates naturally. For
larger defects, such as surgical removal of a

large bone cyst, a bone graft may be needed
to aid in healing. Historically, bone grafts
have been taken from other parts of the body
and shaped for the new defect. This method,
autograft bone transplantation, has many
drawbacks such as risk of donor and recipient
site complications and inexact fit of the graft
[6].
By using stem cell therapy to add
MSCs to bone defect sites, the Dhar lab at the
University of Tennessee, Knoxville College
of Veterinary Medicine works to develop
treatments that circumvent the risks
associated with autograft bone tissue
transplant. Further, the characteristic
potential of stem cells makes them ideal for
use in more novel therapies, which our lab
endeavors to discover and expand upon.
The ultimate goal for our research is
to develop medical procedures in humans.
The road to human trials, however, is
understandably long and difficult. Before this
is a possibility, treatments must be explored
in small and large animal models such as
mice and goats. Our lab has shown promising
success of several therapies in animal
models, and we have begun to use these
techniques on large animal veterinary
patients [7] [8].
MC 3T3-E1 is a cell line of mouse
(Mus musculus) calvaria preosteoblast cells.
Commonly used for studies concerning bone
differentiation and development, the
textbook Principles of Bone Biology refers to
them as “one of the most convenient and
physiologically relevant systems for study of
transcriptional
control
in
calvarial
osteoblasts.” MC 3T3-E1 is a spontaneouslyimmortalized cell line that behaves as
immature, committed osteoblast cells. The
cell phenotype is very stable so long as stocks
are rigorously maintained [9].

Science uses models to reliably
simulate a system that would be too timeconsuming, difficult, expensive, or otherwise
inappropriate to test as a whole. Similarly, it
would be inappropriate to test an entirely
novel treatment method on a group of lab
animals. Instead, treatments and new
questions should first be explored in vitro
with a suitable line of cells as a model. That
starting point is the goal of this project – the
establishment of an in vitro model for stem
cell-mediated bone regeneration in our lab.
Here, we use MC 3T3-E1 mouse
preosteoblast cells towards this end. The cells
are characterized to confirm and explore
ideal conditions; they are studied to establish
factors and time points in the process of
differentiation; and they are used in ongoing
projects to visualize them in vitro and test
new therapeutic materials.

inactivated the trypsin by adding 5mL of
media. Next, we pipetted the resulting 10mL
into a 50 mL conical tube and centrifuged it
at 3000 RPM for 10 minutes. We found that
cells have a tendency to form aggregates after
centrifugation, especially when centrifuged
in smaller 15 mL tubes. The supernatant was
removed following centrifugation, the pellet
was disturbed and suspended in 2 mL of
media, and the suspension was chilled on ice
for 10 minutes. If cell aggregates persisted
after thorough mixing, they were removed by
micropipette.
Counting

Characterization

We diluted cells 1:20 with trypan blue
(20 L cell suspension in 380 L trypan blue)
and counted by adding 10 L of the dilution
to a hemocytometer and counted 5 of the
1mm2 grids which held 100 nL each. We
calculated total cells by the formula
1
1
𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠
𝑐𝑜𝑢𝑛𝑡 ∗ 20 ∗ ∗
∗ 106 =
5 100
𝑚𝐿

Establishment

Growing cells

One million cryopreserved MC 3T3E1 cells were purchased from American
Type Culture Collection (ATCC) in August
2015. After returning the cells to liquid
nitrogen for one month, we removed and
quickly thawed them in a 37C water bath.
The thawed cells were added to 10mL of
media, placed in a 75 cubic centimeter cell
culture flask (T75), and incubated at 37C
with 5% CO2. We changed the cell media
every 48 to 72 hours.

The primary media used to grow cells
was alpha Minimum Essential Medium
(MEM) with 10% US qualified, heat
inactivated fetal bovine serum (FBS) and 1%
penicillin/streptomycin antibiotic mixture
(pen/strep; 10,000units/mL pen; 10,000
g/mL strep). Media was stored at 4C and
warmed before addition to cells. Cells did not
grow well when seeded at low density (below
5000 cells/cm2) which suggests a dependence
on cell-cell interactions for normal
proliferation. Healthy cells maintained a
relatively round morphology (Figure 1.) with
few instances of cell death. The MC 3T3-E1
cells proved to grow very quickly. 300,000
cells plated in a 75mm flask reach numbers
of 2.3 million (stdev 250,000) cells after
incubation for 5 days.

Passaging
Once the cells reached confluency,
we washed the cells with Hank’s Balanced
Salt Solution (HBSS), removed cells from the
flask surface with with 5mL of 0.25% trypsin
incubated at 37C for two minutes, and then
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Figure 1. The cell counts from each replicate
were divided by that replicate’s maximum count
to show relative proliferation. Cells were
incubated for 5 days in MEM with pen/strep and
three different types of FBS. 1. US qualified, heat
inactivated FBS 2. Non US qualified, heat
inactivated FBS 3. Non US qualified, Non heat
inactivated FBS.

Figure 2. Images of cells incubated with and
without differentiation factors after staining with
Alizarin Red. 2a. undifferentiated cells after 20
days of incubation in regular media. 2b. cells
after 14 days of incubation with differentiation
factors. 2c. Cells after 20 days of incubation with
differentiation factors.

Serum Test

Differentiation

We wanted to know if the type of FBS
used has an effect on MC 3T3-E1
proliferation. We tested three types of serum
with MEM and pen/strep:

Stem cell therapy of the skeletal
system largely has the goal of using stem
cells to regenerate healthy bone tissue in the
patient. This differentiation process would
happen naturally in the body by diffusion of
factors that lead to differentiation into bone
cells. To study this process and see how
treatments affect bone differentiation, our lab
must reliably simulate this development in
vitro. We sought to determine a set of factors
and a base timeline for bone formation in
these cells.

1. US qualified, heat inactivated FBS
2. Non US qualified, heat inactivated FBS
3. Non US qualified, non heat inactivated FBS

We found slight variation in the relative
proliferation, but we show no evidence to
support preferential use of US qualified, heat
inactivated FBS (#1), the most laborintensive
and
expensive
option.
Consequently, we suggest the use of non US
qualified, non heat inactivated FBS (#3) as it
is the most cost effective (figure 2.).

Growth

Results

Citing the work of Kanzaki et al., we
found that the following concentrations of
factors leads to ossification of MC 3T3-E1
cells [10]:

After
incubation
in
the
aforementioned factors, we show that the MC
3T3-E1 cells begin the process of bone
differentiation. By the 7th day of growth in
differentiation media, cell morphology
noticeably changes, and the cell monolayer
tends to develop into a swirling pattern
compared to undifferentiated controls. Upon
fixing and staining, we found that cells grown
in the 6-well plates begin depositing calcium
after approximately 14 days of incubation in
the differentiation factors (Figure 2b.). By
the 16th day, the amount of calcium deposits
significantly increases. By 20 days, the
Alizarin Red calcium staining is very heavy
(Figure 2c.). We found that specific culture
conditions, such as initial density or culture
surface, had a large impact on the timeline of
cell differentiation. For example, cells grown
at 7,074 cells/cm2 in 60 mm, biolite
individual tissue culture dishes purchased
from Thermofisher took significantly longer
to deposit calcium. (21 days compared to 14
days). For the sake of this experiment, results
are shown from 6-well plates.





50 g/mL ascorbic acid
10 mmol/L β-glycerophosphate
10 nmol/L dexamethasone

We tested for bone differentiation by
growing MC 3T3-E1 cells in 6-well plates at
initial density of 20,790 cells/cm2. The 6well, 9.62 cm2 well plates were purchased
from Thermofisher. Every 36 to 48 hours,
half of the wells were fed differentiation
media with the above concentrations of
factors, and half were kept as controls and
grown in normal media.
Staining
We fixed the cells for staining at time
points between 7 and 24 days. For washing,
fixing, and staining, approximately 1.5mL of
each reagent was added by plastic pipette. We
washed the cells twice with HBSS and then
fixed them with 4% paraformaldehyde for 10
minutes at room temperature. Following this,
we washed two additional times with HBSS
and then added Alizarin Red stain. After cells
were stained for 30 minutes, we removed
Alizarin Red, washed twice with HBSS, and
allowed the stained plates to dry. As per the
manufacturer’s directions, the Alizarin Red
solution was prepared by adding 1.7 g of
Alizarin Red to 100 mL of DI H2O. The pH
was then adjusted to 4.1 to 4.3 with
ammonium hydroxide. The final volume was
brought to 50 mL. Alizarin Red is a calcium
specific stain. Adding it to cells that are
becoming bone tissue allows us to visualize
calcium deposition and infer ossification.

TOB concentration effect on 3t3-E1 cells
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Figure 3. MTS assay results from cells grown in different concentrations of tobramycin. Tobramycin is toxic
to cells above 360 g/mL which is well above expected in vivo level; this suggests low toxicity to MC3T3E1 cells.

Tobramycin dose curve

Methods

When surgeries are performed on
animal models or in veterinary medicine for
stem cell transplantation, these patients are
often given antibiotics post operation to
prevent infection. One of the most commonly
used antibiotics for this end is Tobramycin,
an aminoglycoside antibiotic. Tobramycin
inhibits protein synthesis in gram-negative
bacteria by irreversibly binding to the 30S
ribosomal subunit [11]. As part of our goal to
establish MC 3T3-E1 cells as a dependable
model in our lab, we wanted to ensure that the
drug to be used during subsequent in vivo
models does not adversely affect MC3T3-E1
proliferation.

We seeded 96-well plates with
2200 cells/well at a density of 6,832
cells/cm2. We fed the cells media with
MEM and 10% FBS, but without antibiotic
to avoid error caused by drug interaction such
as degradation of tobramycin by penicillin
[12]. Recognizing the risk of growing cells
without antibiotics, extra care was taken to
avoid bacterial contamination. We waited 24
hours to ensure that cells attached before
adding TOB; at that point, cells were given
TOB at concentrations of 0, 0.4, 5, 80, 360,
720, and 1440 g/mL. We quantified
proliferation by MTS assay, a colorimetric
method where MTS tetrazolium compound is
reduced
by
NAD(P)H-dependent
dehydrogenase enzymes in metabolicallyactive cells. This results in a change in
absorbance at 490 nm corresponding to the

cell count [13]. We took readings in triplicate
on days 4, 8, 14, and 28.
Results
Cells grown between 0 and 360
g/mL of TOB showed no diminished
proliferation. At concentrations of 720 and
1440 g/mL, MC3T3-E1 proliferation
suffered significantly. Even at the highest
tested concentrations, the cells were less
affected by TOB at earlier time points but
greatly affected at later points (Figure 3.).
In vivo levels of TOB would be
unlikely to exceed 10 g/mL [14]. Even if an
injection of TOB were given directly or near
to the site of stem cell transplant, our data
show that short-term exposure to TOB
presents less toxicity compared to long-term
exposure. These findings suggest little risk
associated with in vivo use of TOB with
MC3T3-E1 cells.

Future directions
Visualization
Working with Dr. Tom Masi at the
University of Tennessee Medical Center, we
are developing a DNA vector to allow
visualization of bone cell differentiation in
real time without fixing the cells i.e. without
having to stop the experiment. The completed
DNA vector will have two fluorescent
protein genes, an m-cherry gene (Excitation
wavelength: 587 nm, Emission: 610 nm) and
a green fluorescent protein gene (GFP)
(Excitation: 395 nm, Emission: 509 nm). The
m-cherry gene will be constitutively on so
that undifferentiated cells fluoresce red. The
GFP gene will be under the control of the
osteocalcin promoter. Osteocalcin is a
protein synthesized by osteoblasts and is

Figure 4. DNA vector makeup for 3T3-E1 bone
differentiation visualization. As transfected cells
differentiate, the fluorescence should change
from red to green.

associated with bone mineralization [15].
Figure 4. Shows the DNA vector makeup.
When the 3T3-E1 cells begin functioning as
osteoblasts, the cell fluorescence should
change. This will allow us to visualize the
process of bone differentiation in living cells.
We have optimized a procedure for
the transfection of a positive control plasmid
with a constitutively active m-cherry gene
(Figure 5.). We used polyethylenimine (PEI)
as a transfection reagent. We experimented
with different ratios of DNA to PEI (1:1, 1:2,
1:3) and found that the 1:3 ratio provides the
best degree of transfection. Additionally, we
tested to see the ideal time of incubation with
DNA and PEI (2 hours, 6 hours, 24 hours),
and found 6 hours to be the most successful.
To transfect cells in 24 well plates seeded at
25,000 cells/ cm2, we changed all cell media
to antibiotic-free. For 1:3 ratio, we added
24uL of 1mg/mL PEI solution to 50 uL
MEM to vial 1.

Figure 5.
Preliminary experiments show
successful transfection of the positive control
plasmid with only m-cherry using PEI

In vial 2, we added 8uL of 1ug/mL DNA to
50 uL MEM. We then combined vials 1 and
2 and allowed them to rest at RT for 10
minutes. 33 uL of this mixture was added to
each well and removed after 6 hours.
Biomaterial
Our lab has begun testing novel
treatments using 3T3-E1 cells as a model.
With the Nanotechnology Center at
University of Arkansas at Little Rock, we are
testing the potential use of a polymerhydroxyapatite biomaterial for use in stem
cell-mediated bone regeneration. In this
collaboration, our labs hope to develop a
material that can be transplanted into bone
defects along with mesenchymal stem cells.
Ideally, the biomaterial would provide a
slow-degrading scaffold onto which new
bone could grow. By adding stem cells to the
material, this process could be expedited for
quicker and better healing.
We are assessing the cytotoxicity of
the material, and we are determining the ideal
ratios of polymer and hydroxyapatite for
ideal cell infiltration (Figure 6.).

Figure 6. Cytoplasmic staining of MC 3T3-E1
cells grown on the polymer-hydroxyapatite
biomaterial.

Conclusion
Stem cell therapies continue to
revolutionize many fields of medicine. To
build that momentum, research must
continue to be done into this promising field.
Central to any biomedical research is the use
of models to simulate how a particular
therapy of interest behaves in vivo. A model
should be relatively simple and wellcharacterized. By having well-defined
models, one is able to answer important
questions without risking resources or lives
in later trials.
The research into many details
concerning MC 3T3-E1 cells has given that
crucial definition to the Dhar lab. We have
shown the characteristics and ideal
conditions of these cells; we have shown
inductive factors and timelines for their
differentiation into bone tissues; we have
shown how they respond to drugs that will be
used in subsequent in vivo trials; and we are
using these findings to discover new ways of
visualizing them and of using them in
regenerative medicine. The use of the MC
3T3-E1 cell line will serve as a crucial tool to
explore many new therapies in the Dhar lab
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